Acasti Pharma Inc (ACST)
2.92
-0.01
(-0.29%)
USD |
NASDAQ |
Apr 26, 16:00
2.92
0.00 (0.00%)
After-Hours: 18:23
Acasti Pharma Enterprise Value: 2.412M for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 25, 2024 | 2.412M |
| April 24, 2024 | 2.144M |
| April 23, 2024 | 1.956M |
| April 22, 2024 | 1.674M |
| April 19, 2024 | 1.862M |
| April 18, 2024 | 3.742M |
| April 17, 2024 | 4.869M |
| April 16, 2024 | 6.374M |
| April 15, 2024 | 6.468M |
| April 12, 2024 | 6.891M |
| April 11, 2024 | 6.844M |
| April 10, 2024 | 6.844M |
| April 09, 2024 | 6.844M |
| April 08, 2024 | 6.844M |
| April 05, 2024 | 6.844M |
| April 04, 2024 | 6.844M |
| April 03, 2024 | 6.656M |
| April 02, 2024 | 7.126M |
| April 01, 2024 | 7.314M |
| March 28, 2024 | 7.079M |
| March 27, 2024 | 6.844M |
| March 26, 2024 | 6.844M |
| March 25, 2024 | 6.938M |
| March 22, 2024 | 6.844M |
| March 21, 2024 | 6.844M |
| Date | Value |
|---|---|
| March 20, 2024 | 6.844M |
| March 19, 2024 | 6.844M |
| March 18, 2024 | 6.844M |
| March 15, 2024 | 6.656M |
| March 14, 2024 | 6.938M |
| March 13, 2024 | 6.844M |
| March 12, 2024 | 7.126M |
| March 11, 2024 | 6.374M |
| March 08, 2024 | 6.844M |
| March 07, 2024 | 6.844M |
| March 06, 2024 | 6.938M |
| March 05, 2024 | 6.891M |
| March 04, 2024 | 7.220M |
| March 01, 2024 | 7.173M |
| February 29, 2024 | 6.28M |
| February 28, 2024 | 6.844M |
| February 27, 2024 | 6.186M |
| February 26, 2024 | 6.562M |
| February 23, 2024 | 6.374M |
| February 22, 2024 | 6.515M |
| February 21, 2024 | 6.28M |
| February 20, 2024 | 4.118M |
| February 16, 2024 | 5.904M |
| February 15, 2024 | 3.648M |
| February 14, 2024 | -0.2996M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-19.60M
Minimum
Dec 12 2022
227.05M
Maximum
Dec 20 2019
33.06M
Average
9.018M
Median
Enterprise Value Benchmarks
| Aurinia Pharmaceuticals Inc | 353.80M |
| Edesa Biotech Inc | 9.905M |
| Lexaria Bioscience Corp | 23.05M |
| Xenon Pharmaceuticals Inc | 2.387B |
| ESSA Pharma Inc | 128.62M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.391M |
| Total Expenses (Quarterly) | 3.043M |
| EPS Diluted (Quarterly) | -0.0542 |
| Earnings Yield | -156.8% |
| Normalized Earnings Yield | -170.79 |